The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001183370
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
20/08/2026
Date registered
Help: Date registered
23/09/2026
Date last updated
Help: Date last updated
23/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
23/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A pilot study assessing the safety, practicality and participant experience of a non-invasive DermR Patch for collecting samples from basal cell carcinoma before surgical removal.
Scientific title
Safety, Feasibility and Participant Experience Study in adults of a
Non-Invasive DermR Patch Device for Sampling Dermatologist-Diagnosed Basal Cell Carcinoma Prior to Standard-of-Care Surgical Excision.
Additional trial identifiers [1] 318172 0
STRATA001
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Dermatologist-diagnosed basal cell carcinoma (BCC) 343227 0
Condition category
Condition code
Cancer 339329 339329 0 0
Non melanoma skin cancer

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Potential participants will be identified by authorised MoleMap clinical staff from patients with dermatologist-diagnosed basal cell carcinoma (BCC) who are already scheduled for standard-of-care surgical excision. Eligible patients will be contacted by authorised MoleMap staff, provided with the Participant Information and Consent Form in advance, and invited to attend one dedicated study visit before surgery. No study-specific dermatologist consultation is required.

The intervention will be delivered once during a single 45–60-minute visit at a participating MoleMap clinic. Before any study-specific procedure is undertaken, a trained and delegated MoleMap Melanographer will confirm eligibility, answer any remaining questions and ensure that informed consent has been completed electronically.

The Melanographer will clean the target lesion and the clinically normal-looking skin sampling site using saline-soaked gauze and allow each site to air dry.

Four DermR® Patch samples will be collected sequentially during the same visit:

• two samples from the target BCC lesion scheduled for standard-of-care surgical excision; and

• two samples from clinically normal-looking skin within the same anatomical region, which will serve as within-participant control specimens.

For each sample, the Melanographer will stretch the skin so that it is taut, place the DermR® Patch in full contact with the skin, apply pressure and maintain contact for 15 seconds, and then remove the Patch immediately. Total Patch-to-skin contact time will be approximately 60 seconds across the four applications. The participant will not wear the Patch after application, no Patch will remain attached between applications or after the visit, and there are no Patch-related restrictions on the participant’s activities. No separate application or removal visit is required.

Immediately after each Patch is removed, the specimen will be placed in its designated collection tube. Specimens will be labelled using the participant’s Study ID and relevant specimen information, packaged with the required chain-of-custody documentation, and sent for RNA extraction, pre-sequencing RNA quality assessment and sequencing-based molecular analysis.

The participant will complete the study-specific Participant Study and Procedure Experience Interview Questionnaire immediately after all four Patch applications have been completed. The application sites will be inspected and any local skin adverse events will be recorded. No confinement, blood sampling, pharmacokinetic testing, vital-sign monitoring or activity restriction is required.

Safety information will be collected from the first DermR® Patch application through 24–72 hours after application. Any relevant event first identified or reported at the participant’s next routine clinical contact will also be recorded in accordance with the study adverse-event procedures. No separate mandatory safety visit is required.

Standard-of-care surgical excision and histopathological assessment will occur separately, generally 1–2 weeks after the study visit. Surgery is not part of the study intervention and will be performed by the participant’s treating clinical team as part of usual care. Participation will not delay or alter the surgery or other clinical care. The resulting routine histopathological diagnosis may be used as contextual information for the exploratory molecular analyses.
Intervention code [1] 335061 0
Diagnosis / Prognosis
Intervention code [2] 335361 0
Treatment: Devices
Description of the comparator or control
No separate control group. Within each participant, molecular findings from the BCC lesion sample will be descriptively compared with matched clinically normal skin samples.
Control group
Active

Outcomes
Primary outcome [1] 346538 0
Participant-reported comfort during DermR® Patch application.
Timepoint [1] 346538 0
Immediately after completion of all four DermR® Patch applications during the single study visit.
Primary outcome [2] 346623 0
Participant-reported tolerability of DermR® Patch application, including any application-related discomfort or concerns.
Timepoint [2] 346623 0
Immediately after completion of all four DermR® Patch applications during the single study visit.
Primary outcome [3] 346624 0
Incidence of local device-related skin adverse events following DermR® Patch application.
Timepoint [3] 346624 0
From the first DermR® Patch application through 24–72 hours after application. Any relevant event first identified or reported at the participant’s next routine clinical contact will also be recorded.
Secondary outcome [1] 466776 0
Sample adequacy rate, defined as the proportion of DermR® Patch samples meeting all predefined RNA quality and quantity criteria required for sequencing.
Timepoint [1] 466776 0
After central laboratory receipt, RNA extraction and completion of the pre-sequencing sample-quality assessment, and before sequencing. The assessment applies to DermR® Patch samples collected from both the BCC lesion and clinically normal-looking skin.
Secondary outcome [2] 466777 0
Sequencing success rate, defined as the proportion of DermR® Patch samples generating analysable sequencing data that meet the predefined sequencing quality criteria.
Timepoint [2] 466777 0
After sequencing and completion of sequencing quality control for samples collected from both the BCC lesion and clinically normal-looking skin.
Secondary outcome [3] 466778 0
Preliminary genomic signature distribution in BCC lesion samples. Descriptively characterised using sequencing-derived molecular profiles.
Timepoint [3] 466778 0
After sequencing quality control and once the routine histopathological diagnosis from the BCC tissue removed during the participant’s separately scheduled standard-of-care surgical excision is available.
Secondary outcome [4] 466779 0
Within-participant descriptive comparison of sequencing-derived molecular profiles from the BCC lesion and matched clinically normal skin.
Timepoint [4] 466779 0
After central laboratory receipt, RNA extraction and completion of the pre-sequencing RNA quality and quantity assessment, and before sequencing.
Secondary outcome [5] 468445 0
Additional primary outcome: Participant-reported acceptability of the DermR® Patch procedure.
Timepoint [5] 468445 0
Immediately after completion of all four DermR® Patch applications during the single study visit.
Secondary outcome [6] 468446 0
Additional primary outcome: Participant-reported discomfort associated with the DermR® Patch procedure.
Timepoint [6] 468446 0
Immediately after completion of all four DermR® Patch applications during the single study visit.
Secondary outcome [7] 468447 0
Additional primary outcome: Participant-reported concerns regarding the DermR® Patch procedure.
Timepoint [7] 468447 0
Immediately after completion of all four DermR® Patch applications during the single study visit.

Eligibility
Key inclusion criteria
Adults aged 18 years or older; able to provide written informed consent; dermatologist-diagnosed BCC scheduled for routine surgical excision; target lesion of suitable size and location for secure Patch placement on the face (excluding nose and ears), neck, back, upper arm, forearm or lower arm; willing to undergo Patch sampling before excision and permit research use of genomic data.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Lesion on a mucosal surface or another location preventing secure placement; target lesion on nose, ears, décolletage, shins, feet or dorsum of hand; active infection, ulceration, bleeding or other site condition likely to interfere with sampling or safety; known allergy to DermR Patch materials or adhesives; any condition that, in the investigator’s judgement, makes participation unsuitable.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 322736 0
Commercial sector/Industry
Name [1] 322736 0
DermR Health Solutions Pty Ltd
Country [1] 322736 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
DermR Health Solutions Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 325657 0
None
Name [1] 325657 0
Address [1] 325657 0
Country [1] 325657 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 321177 0
Bellberry Human Research Ethics Committee C
Ethics committee address [1] 321177 0
Ethics committee country [1] 321177 0
Australia
Date submitted for ethics approval [1] 321177 0
13/07/2026
Approval date [1] 321177 0
18/09/2026
Ethics approval number [1] 321177 0
2026-07-1188

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 152922 0
Dr Rebecca Saunderson
Address 152922 0
Consentic, International Tower 3, Level 17, 300 Barangaroo Ave, Barangaroo NSW 2000
Country 152922 0
Australia
Phone 152922 0
+61 2 9719 2936
Fax 152922 0
Email 152922 0
Contact person for public queries
Name 152923 0
Stefan Mazy
Address 152923 0
DermR Health PO BOX 8 ALEXANDRIA NSW 1355
Country 152923 0
Australia
Phone 152923 0
+61 0425199277
Fax 152923 0
Email 152923 0
Contact person for scientific queries
Name 152924 0
Stefan Mazy
Address 152924 0
DermR Health PO BOX 8 ALEXANDRIA NSW 1355
Country 152924 0
Australia
Phone 152924 0
+61 0425199277
Fax 152924 0
Email 152924 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: There is no current plan to share individual participant data from this pilot study. Study findings will be reported in aggregate form only.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.